Foster City, California: September 15, 2014 – Diabetes Technology Society (DTS) is pleased to announce that it will hold a public meeting regarding payer liability for funding inaccurate blood glucose monitors. This meeting, which is free to attend, is an extension of the DTS Surveillance Program for Cleared Blood Glucose Monitors, which was launched on May 20, 2014. The event will be held on November 5, 2014 in Bethesda, Maryland, at the Residence Inn Downtown Bethesda.
After a product has been cleared by the Food and Drug Administration (FDA), there is currently no systematic post-market surveillance program available to monitor ongoing product quality. As a result, some patients diagnosed with diabetes are using blood glucose meters that do not perform to the standard of their FDA clearance. These devices can interfere with the patient’s ability to accurately monitor their blood glucose levels, which can lead to incorrect decisions about treatment and therefore adverse health effects.
The surveillance program will provide an independent assessment of the performance of cleared blood glucose monitors and generate information that can assist patients, payers, and healthcare providers in making informed product selections. The meeting on November 5, 2014will cover the outcomes and consequences for payers and patients who use products that have not maintained their performance level since being cleared by the FDA. The meeting will include perspectives from payers, clinicians, attorneys, scientists, the FDA, patients, and other members of the diabetes community.
Admission to the meeting on November 5, 2014 is free; however, registration will be necessary to attend the event as space is limited. To register, please visit: www.diabetestechnology.org/